| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Product revenue, net | 49,504 | 39,503 | 28,519 | 16,352 |
| Cost of revenue | 6,190 | 5,038 | 3,724 | 2,356 |
| Gross profit | 43,314 | 34,465 | 24,795 | 13,996 |
| Research and development | 7,027 | 9,076 | 9,184 | 8,693 |
| Selling, general and administrative | 51,558 | 85,313 | 94,474 | 76,099 |
| Total operating expenses | 58,585 | 94,389 | 103,658 | 84,792 |
| Loss from operations | -15,271 | -59,924 | -78,863 | -70,796 |
| Interest income | 1,413 | 1,787 | 2,640 | 3,711 |
| Interest expense | 16,108 | 17,518 | 18,071 | 18,484 |
| Other expense, net | -7 | -155 | -22 | -8 |
| Total other expense | -14,702 | -15,886 | -15,453 | -14,781 |
| Net loss and comprehensive loss | -29,973 | -75,810 | -94,316 | -85,577 |
| Net loss per share, basic | -0.41 | -1.05 | -1.31 | -1.32 |
| Net loss per share, diluted | -0.41 | -1.05 | -1.31 | -1.32 |
| Weighted-average shares of common stock outstanding, basic | 73,396,435 | 72,466,203 | 71,969,411 | 64,627,847 |
| Weighted-average shares of common stock outstanding, diluted | 73,396,435 | 72,466,203 | 71,969,411 | 64,627,847 |
Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. (PHAT)